Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
Mechanisms of Belatacept (Nulojix) Effect on Alloimmunity and Antiviral Response After Kidney Transplantation - (BMS Study# IM 103-309)
Sponsor: Bristol-Myers Squibb
This PHASE4 trial investigates Renal Transplant Rejection and is currently completed. Bristol-Myers Squibb leads this study, which shows 12 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
May 2021 — Jan 2023 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE4
▶ Show 7 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
-
Jan 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE4
-
Jan 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE4
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE4
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
-
Feb 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- University of California, Los Angeles
For direct contact, visit the study record on ClinicalTrials.gov .